AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
1. AstraZeneca's Q4 sales hit $14.89 billion, exceeding expectations. 2. Oncology sector grew 27%, driven by Tagrisso and Lynparza. 3. CVRM sales up 16%, with Farxiga showing strong performance. 4. Respiratory revenue climbed 27%, boosted by Tezspire and Saphnelo. 5. China sales dipped 1%, but legal issues have minor impact.